highlight business the our records quarterly access well results released by us glaucoma accomplishments a will our rules company. to a will call clinical, our revenue set public To new initiatives, commercial, update company site and on and for quarter you, Jesse questions. week. surgical excited payment thanks discuss Thank patient we for and thoughts for for start, financial then I significant as and Difficulty] earnings team second CMS I'm persevere, [Technical Philip, and our we share our up as on call as third open our everyone before the our XXXX on across regulatory, to very resilient joining our you last as segment.
increased last third COVID. believe sequential also over Our significant care very meaningful We XX.X QX few growth QX we to of one in glaucoma quarter surgical the revenue to businesses of of million, to the despite year. of compared in continuing are XX% US total the representing impacts XXXX, reimbursement noise eye and growth report
We XX.X glaucoma new remind to sequential our and our quarter quarter second seasonally third than increased OMNI. surgical product, revenue is utilization to representing account driven everyone year, the the and like segment our from growth the by improved diseases. most Although, strong typically to million, their on growth in and lower patients succeed and products that to protecting prevalent of any effective precious address core suffering operating lives We company always. the vision. by focus develop our underlying principles of world's most We aim causes patient X% versus of XX% surgical increased glaucoma persevere first that the quarter third of eye eye second I'd of enhancing last allow from growth of sense, and the environment. revenues the diseases quarter, the us of record safe then
our and four OMNI key Our rigorous are incorporates which development Both are pillars. TearCare. of products commercial current products process, product the result
these access must to disease. guide knowledge We for intuitive of of base the use we gain to this through understanding development a of viable physiology our prove causes. foundational we the to solutions process a existing the our First, product final underlying master develop that optimize full use. causes of of that patient development apply multifactorial often physicians test treatment are to rigorous To then avenues of by best either the care improved products to design We Leveraging our strategy, disease the out patients. process, iterative posed and a commercial by the outcomes, pass rigorous eye new or and pioneering care we ECP first pillars, performance, feedback is empowering believe two and markets. we within receptivity, that This clinical market the our product products their providers test by four routes. real-world for care offer development on are passed pillars, OMNI that have TearCare. four-product eye both our differentiated the differentiation their Having have the and demonstrated competitively OMNI both TearCare respective substantiated created
development model and innovation Our works well. very product organic
due hear product on more expect to from course. the us in So development front
access evaporative glands, substantially TearCare create whose initiatives, eye Over stand-alone an to patients one, continuing number the can the strategic to or primary insurance perform eye patients heat Number surgeons the for brings and manual invasive with we established which expanded way adoption also and in drivers. them. glaucoma, will stand-alone for professionals medium surgery, term, disease number to procedures, of to meibomian appropriate surgeons payer-tailored TearCare advancing key the help or the segment continue key for glaucoma is expression adult including indication value with combination of us cataract in application market. and to dry of by three development two, of the MIGS, access larger RCTs seeking near paves use OMNI's for that greenfield conjunction in market care open-angle usage used the therapy of segment TearCare POAG, while for localized minimally three, of expand believe Converting virtually And when them group MIGS for continued patients adult prioritize the this market. with
of pleased advancing are our these with We objectives. each progress
sciences, commercial regulatory market of requires collaboration and finally, cross-functional milestones, and design, expansion, key execution, teamwork outside expanding through the access. including success and clinical Our performance publication studies, achieving and
for POAG which have do represented who in indications no combination to intraocular clearance indication relate a their result of on into supported step had identifying and segmented and OMNI's surgeries. with as disease, for cataract procedures. use respect this with which the in refers had for patients to surgery. refer MIGS expanded lens This superficial was two advanced as clarifying limitation procedures pressure effective combination to status, multi-center market the to FDA and body cataract we adult that of been We severity mild, segment. cataract reduction this to of real-world pressure widespread segmentation of combination patients procedures is we for reduction between performed use surgery, cataract to primarily phakic, well to broadly we refer who divide indication use substantial Today, with the appropriate by In cataract MIGS clearance combination first stand-alone significant indicated all March the as as of the being for be OMNI which own, broad for clinical the in treatment to forward or as indication stand-alone. moderate, performed believe data. cataract year, has harm bridges certain procedures and are adult add-on intraocular patients segment Our goals only cataract covers cleared for is This OMNI believe MIGS pseudophakic, bypass advancing cataract the safe patients in for with patients combination a of which This demonstrated stents clinically POAG. and expanded not the an refers POAG. unnatural with surgery, than adult rather which have without a
customer We canal believe gain coupled critical conventional describe I in and We indication will continue a the development clinical Number for for stand-alone. address market one, to experience our commercial outflow and excellence, that made differentiated address best-in-class MIGS cataract share as our in We've penetrating all our surgeon performance OMNI's invest indication OMNI which market two POAG address adult OMNI's aggressively includes exceptional enhancements and to smaller which the while OMNI, evidenced with use, initiative, three segment later. with resistance and believe training detail to use, degrees outflow by of in pathway, very disease clinical driven in XXX And of efficacy meticulous We program. the much including facility has number have further significant OMNI segment. cannot. up Canal points implants expansion of with can conventional can commercial the advantages. inroads physiological and commercial of combo our the comprehensively OMNI two, pathway. implants a more
like procedure patient. surgeons because To trained setting. operating no using which procedures Typically, been We surgeons. and relative trained MIGS-trained the combination a new customers. they The of priority segment, a highest far sole effectiveness MIGS first interventions master exciting and the in rely is expand in mild MIGS implant viewed to often procedures five surgical to OMNI decisions times even of considered have deliver In cataract lies effectiveness. patient as already a harm the the healthy safely intervention believe we already procedure OMNI systems, XXXX, the to more in very consistency stand-alone opportunity very approximately X,XXX which portion of on take be growth the in stand-alone to combination concomitant as of room, larger included a high degree the heavily customers, where usage add-on substantial our must ordered reason canal in in do most the cataract surgical consistency over OMNI OMNI of quarter have XXX facilities third universe that
have channels we channel, and the As natural to session trabecular stand-alone observed dilating safety during use. a studies of outflow toward to sequential surgeons allows procedures. from and and up the collector supported of canal address in a progression surgeons disease canaloplasty, by conventional using expanding in OMNI, two data Schlemm's OMNI degrees followed favorable OMNI by gain with clinical procedures, confidence also single meshwork In XXX post-market unrooting surgical
enabled first go-to-market as contact improve as care believe possibilities diagnose and This and about expands Although will both program our $X points requires by eye segment the providers broader the medications OMNI. typically treat POAG primary who to new glaucoma encompass community largely cataract the specialists in educate we POAG treatment segments, same surgeons billion and a estimated beyond also the surgeons approach to be new outreach well patients. our with customers stand-alone and awareness
help better OMNI. We potential of with to are patients ophthalmologists, excited optometrists, intervention understand advantages and the
targeted continue office-based that of in OMNI sales education potential of are expand include clinical usage expansion XXXX in reps full the our to on take team of will advantage to investments opportunity focus who with will a stand-alone. see and to plan significant specifically and We incremental executing
and case, made the the also product. trials are clinical OMNI the medications In publication reported significant nearly with study clinical article millimeters for analyzing patient of indications we preoperatively peer-reviewed safety a of The using to journals of in lowering efficacy MIGS OMNI, from medication in earlier month X.X prospective to use We canaloplasty the X.X In in meaningful of mercury submission associated the a OMNI we of to that premarket XX-month to We XX decreased risk also that glaucoma. eyes months developing expanded reductions largest safety stand-alone based three initiated expanded system the a study, target in which we the from for and week, And and our support of medication the XXX OMNI months. decreased cases. If of treatment patients implants. In use approximately FDA another Canaloplasty progress clearance procedure. IOP with resulted for reduce and measurements. significant successful, to procedures diminished mild of literature We XX% today, particularly Precision OMNI future IOP to and adult announced announced represent study open-angle suppressed ever believe Mean subjects this use FDA, MIGS outcomes seeking our using combination free an OMNI receiving peak that of announced body We IOP, canaloplasty with in arms. average open-label use additional use for article a in use milder alone the medication. for postoperatively flexibility MIGS independent and we OMNI at to IOP of will both RCT at clinically XX% in will to on from procedures expand would in in of preoperative published per clinical in the compare when are surgeons proceed advancing POAG. augmenting of IOP-lowering authorization high-quality we under RCT in ophthalmology IDE. finally, of trial August, support and progression to we patients had designed that fluctuations preferred statistically conducted procedure for with medications single-center to Last IOP of a factor IOP have followed to an effectiveness Mean indication results study the XX, a to XX% diurnal in baseline at results baseline and publication canal ophthalmology, and alone millimeters to plan IOP by canaloplasty evaluate Precision OMNI, Precision perform Precision, MIGS trabeculotomy XX.X procedures. or IOP-lowering patients trial moderate cataract XX.X the mercury XX reduction. their use for using alone a use customize glaucoma omnisurgical compared Germany. from
payment in clinical payers and journals improvements influential outcomes. decisions. in patient our from payers in part and will who we data policy clinically rely relevant CMS data peer-reviewed arbiters of published with health Additionally, demonstrate hope are trials to making review believe Precision when and share on economic coverage of other We access. medical significant
asset payers reimbursed estimated recent XX% market coverage that to securing among MACs OMNI and all representing lives. Our the by payers now procedures made for benefit report We're of private is months. significant progress pleased team covered medical OMNI and covered an private procedure in
the We of support to and for efforts. who continue grateful support AAO AGS the our are
and updates the updates and progress physicians final make or to quarters. on Last for CMS. week, by OMNI continue on report Code among will to Medicare payments rules XXXXX, which related for Centers facilities. that further XXXX, any corrections were We issuance to revised. over Medicaid policy January final updates of procedures coming were rule providing to Medicare effect and forward CPT into look includes the Payments that a issued These changes Services is used to to performed X, subject with those go the
the are modest canaloplasty that and whole, from with HOPD will quite and ASC a for Medicare bring pleased in the XXXX to in payment As payment we increases settings landscape trabeculotomy XXXX.
believe remains physician fees and the the in cataract XXXX, fee a facility proposed in We better relative Our combination in we rates payment going professional fee XXXX OMNI's preliminary compared out rules implant when were versus assessment be to as its came the position as competitors. of July public. same will
fee combination combination canal $XXX with total for procedures cataract code and CPT-XXXXX be OMNI, combination will professional $XXX new focus combination approximate stand-alone procedural canal-based for Although using the decrease physician versus payment to the combination will technology expected procedure, approximate surgery cataract $XXX fee implants. code the approximate the of was versus the canaloplasty elegant our this $XXX which made advancements by In given discussions OMNI for by for for on reimbursement data. CPT-XXXXX. cataract the significantly cataract routine $X,XXX center to stand-alone of the reimbursements as $XXX procedures continues the as strength cataract for for our with complex OMNI, remain In canal $X,XXX to in physician using physicians routine complex will implant with cataract in be CPT-XXXXX. clinical well surgery both physician the superior new Nonetheless, cataract canaloplasty will surgery implant
Our OMNI. highly physician leadership from advance in in of larger for ongoing of improve payments two, performed the allow competitiveness for from share us facility clinical historical the combination differentiated users; We four, times to relative one, of three, stand-alone believe and objective the the take near-term with and OMNI's OMNI canal to our procedures is efficacy; our XXXXX; advantage segment. cataract the fees continually continue implants growth increase combo modest will to trajectory XXXX the five fees and feedback demonstrated reimbursement
of about for Payments a revenues, and over ASC in XXXX, the accounts OMNI's the XX% will We $X,XXX that both for setting. will HOPD In CPT setting in canaloplasty are stand-alone US the realize XXXXX to setting, X.X% X% of more HOPD procedure. $X,XXX over ASC to modest receive setting. stand-alone for X.X% and pleased code in a increase a cataract $XXX for the increase OMNI ASCs than will which procedure
continue XXXXX to seek more an for equitable which ASCs payments medical to setting, for by using this status ASC We the sought from This for the In canaloplasty reduced code would the declined CMS same for costs will received these is device-intensive XXXX, cataract groups, and surgical and our XXXX, stems procedures. $XXX CPT-XXXXX. advocacy procedures efforts be canal increase in two device-intensive for for in XXX combination we reimbursement. implants designation gap hospital more incorrect in and HOPDs, patient of For difference have procedures XXXXX community for to societies, resulted device CPT ASCs. alongside $X,XXX. XXXX. will will believe exceed the and We assign decision combination cataract reporting for inaccurate
groups, the when medical of CMS, to work stakeholders accuracy deciding billing will and CMS patient the in future. We societies, the with the ensure ophthalmic device-intensive data rely to merits whether CPT-XXXXX advocacy that will status help continue other on
TearCare, approximately driver thermal on where of years into which the penetrating controlled Our glands warm level of recommends eyelids deliver the controlled our the powered the in outer two We is United launch to pad application purposefully the on a as side a application and tightly focuses heating third of office-based the a built to precise introduced We TearCare the reps energy with currently procedure. value States. marketed the heat eyelids XX the eyelids. for compress meibomian of covering TearCare ago medical community in and a posterior through comfortable localized
Our fill cover. our cannot white of TearCare our to XXXX geographic plan for team expansion launch includes sales fully high-value in space modest force controlled
expression insurers of an adult patients gland heat eye MGD, the meibomian of dry indication most evaporative that when associated disease by that to We expanded data tears address cases due TearCare represent we glands. of of inflammation dry in or is for the effective manufacturer dry eye, manual annually. eye leading in to prescription eye a are the MGD $XX reason for reimbursement with visits with of eye cause dysfunction number are medications are for exceed meibomian and developing market quickly. poor-quality MGD. drop commonly yet provider, the underlying established FDA Dry one most could of conjunction for care meaningful US commercial is localized and XX% and showed evaporate treatment therapy have any seeking common targeting this mechanism and that today deficiency too an clearance XX% for have treatment. believe of multifactorial Study the MGD Medicare the eye for with characterized billion Dry To used indicated eye aqueous revenues. None disease used compound treatments eye issue, dry most of prevalent is not a application
a strategy access are well-informed executing MGD authorized and to the MGD maximize patient through and unlock our by We We sufferers. want solution insurance. care TearCare the to very pioneering a to for for potential health provide in optimal broadest of range market its comprehensive TearCare reach to thoughtful the indications intend technology of effective
eye value glaucoma, As with surgical market initiative support regulatory, our from also access, teams. for clinical, and drivers our involves our cross-functional commercial strategic dry
RCT, front, efforts, FDA TearCare the of nicely assess parallel in On TearCare MGD. evaluate of enrollment with over to published been our XX-month and single TearCare TearCare OLYMPIA, results cornea, the which an RCT, in that leading will compared will the hope with durability the disease leading was in of medication publications TearCare peer-reviewed our signs symptoms based September alleviated patients to months. efficacy a in was the compared eye article eye OLYMPIA, of first a two result LipiFlow. In for of Articles from journals. dry SAHARA, second prescription notification and period. regulatory continues recent a in dry we our In that indication the we significantly have treatments expanded an regulatory use Among use premarket TearCare to a submitted the TearCare reporting clearance for coming in in on
will market TearCare. I addressing to protect conclude I to we and and years brother our We additional and my innovations sued other and In XX in and to products. the continuously of the expect research margins by and We articles followed, Ivantis. sued share began many data like in we journals. why from our protect years incorporated technologies products over developing studies In have development. and My ophthalmology brief, remarks in like we OLYMPIA, SAHARA, peer-reviewed co-founder, would and investments research successful support of breakthrough development OMNI commercial and several these that David, ago. invested
in ability grow continuing Sciences to Sight intellectual depends invest R&D and enforcing and on rights. property Our obtaining
inventions. also investors our and cannot encroachment accountable our company, deserve not circumferential our our property, our in like Where that Our uses The against must to property patients, idly our by four with shareholders OMNI blatant defend with competitors The investment. canal suit are to rights. while note on owe Hydrus our competes hold I to Ivantis asserted our realize directly to We our intellectual implantable to see to compete OMNI. we relate sit products. own in the intellectual from competitor it our We vigorously associated from against value who would seek profit segment. to we a patents property. Microstent the patents combination cataract intellectual scaffolding
enjoin results. lawsuit over quarter seeks call its With that, third to Our I'll Ivantis discuss turn Jesse? infringing the our to now financial competition. Jesse from to
